A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib)

Trial Profile

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Brivanib alaninate (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BRISK-PS
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018.
    • 25 Jan 2017 Results (n=334) demonstrating objective response by mRECIST as a predictor and potential, published in the Journal of Hepatology.
    • 13 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top